Downregulation of miR-25-3p and Its Impact on PTAFR and IGF2BP3 Expression in Type 2 Diabetes Mellitus: Implications for Biomarker Discovery and Disease Pathogenesis
Issued Date
2024-01-01
Resource Type
ISSN
19183003
eISSN
19183011
Scopus ID
2-s2.0-85211318276
Journal Title
Journal of Clinical Medicine Research
Volume
16
Issue
11
Start Page
536
End Page
546
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Medicine Research Vol.16 No.11 (2024) , 536-546
Suggested Citation
Rattanapan Y., Nongwa K., Supanpong C., Satsadeedat C., Sai-ong T., Kooltheat N., Chareonsirisuthigul T. Downregulation of miR-25-3p and Its Impact on PTAFR and IGF2BP3 Expression in Type 2 Diabetes Mellitus: Implications for Biomarker Discovery and Disease Pathogenesis. Journal of Clinical Medicine Research Vol.16 No.11 (2024) , 536-546. 546. doi:10.14740/jocmr6099 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/102400
Title
Downregulation of miR-25-3p and Its Impact on PTAFR and IGF2BP3 Expression in Type 2 Diabetes Mellitus: Implications for Biomarker Discovery and Disease Pathogenesis
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: This study is designed to investigate the differential microRNA (miRNA) expression profiles in individuals with and without type 2 diabetes mellitus (T2DM). The focus is on miRNAs that play a crucial role in the onset and progression of T2DM, particularly in glucose metabolism, inflammation, platelet reactivity, and endothelial dysfunction. Methods: Twenty samples were categorized into groups of T2DM and non-T2DM, and miRNA profiling was conducted using microarray analysis. The expression levels of the candidate miR-25-3p, as well as its target genes platelet-activating factor receptor (PTAFR) and insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3), were validated using quantitative polymerase chain reaction (qPCR). Results: The present study revealed a significant reduction in the level of miR-25-3p in the T2DM group compared to the non-T2DM group. This suggests higher levels of PTAFR and IGF2BP3 in individuals with T2DM, indicating a potential biomarker for the condition. Conclusions: The downregulation of miR-25-3p, which is associated with increased PTAFR levels, may contribute to heightened platelet reactivity and inflammation, worsening endothelial dysfunction, and potentially influencing vascular complications in diabetes. Additionally, the upregulation of IGF2BP3 is correlated with insulin resistance and β-cell dysfunction, which may contribute to elevated hyperglycemia and hyperinsulinemia, further aggravating the progression of diabetes. These findings highlight the potential of miR-25-3p and IGF2BP3 as biomarkers for T2DM and suggest their possible relevance for improving diagnosis and treatment strategies.